C4 Therapeutics Inc. (NASDAQ: CCCC) is gaining attention as one of the best biotech penny stocks to buy according to analysts. Recently, Barclays lowered the firm’s price target on C4 Therapeutics to $5 from $10 while maintaining an Overweight rating on the shares. This update was part of the firm’s 2026 sector outlook on biotechnology.
In another development, TD Cowen initiated coverage of C4 Therapeutics with a Buy rating, highlighting the company’s unique position in achieving clinical validation for both molecular glues and heterobifunctional degraders. The firm pointed out that cemsidomide, one of the company’s lead candidates, has shown promising results in Phase 1 data for multiple myeloma, with a 53% overall response rate at the highest dose level.
Looking ahead to 2026, C4 Therapeutics is set to launch the Phase 2 MOMENTUM trial for cemsidomide in combination with dexamethasone in Q1 2026, with potential for accelerated approval. Additionally, a Phase 1b trial in collaboration with Pfizer’s elranatamab is scheduled to begin in Q2 2026. These trials aim to solidify cemsidomide’s position in the treatment landscape for relapsed/refractory multiple myeloma.
Beyond oncology, C4 Therapeutics is leveraging its TORPEDO platform to advance a discovery pipeline targeting non-oncology indications. The company is focused on developing novel therapeutic candidates to degrade disease-causing proteins.
While C4 Therapeutics shows promise as an investment, there are other opportunities in the market. For those interested in AI stocks with potential upside and less downside risk, exploring other options may be beneficial. One such opportunity is highlighted in a free report on the best short-term AI stock.
In conclusion, C4 Therapeutics Inc. (NASDAQ: CCCC) is making strides in the biotech industry with its innovative approach to developing therapeutic candidates. With ongoing clinical trials and a focus on advancing treatments for multiple myeloma and other diseases, the company is poised for continued growth and success in the coming years.
